Alpha Cognition
Vancouver
About Alpha Cognition
Alpha Cognition is a clinical-stage, biopharmaceutical company developing treatments for under-served neurodegenerative diseases. It features ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of Alzheimer’s type, with minimal gastrointestinal side effects and novel routes of administration.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Total funding: $95.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: nasdaq:ACOG
- Website: alphacognition.com
- Phone: (604) 684-3323
Industries & Categories
Biopharma, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/alpha-cognition-95093 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.